GlassScriptPhysician profile
Rebecca Reiser
NPI 1639336795
$2,266.82
in general payments reported to CMS, 2019-2025
23 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $12.02 · 2021: $66.84 · 2022: $167 · 2023: $663 · 2024: $714 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $953.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $300.88 | 2023-2024 | |
| Celgene Corporation | $209.71 | 2023-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $123.66 | 2019 | |
| Ucb, INC. | $94.28 | 2024-2025 | Rystiggo |
| Amgen INC. | $59.85 | 2019 | |
| Pfizer INC. | $59.47 | 2023-2025 | |
| Medtronic, INC. | $58.24 | 2024 | Percept PC Brainsense |
| Jazz Pharmaceuticals INC. | $43.36 | 2022-2024 | |
| Axsome Therapeutics, INC. | $42.02 | 2025 | Symbravo |
| Allergan, INC. | $41.78 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $39.61 | 2023-2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $39.54 | 2024 | Hyqvia |
| Tg Therapeutics, INC. | $34.44 | 2024 | |
| Sk Life Science, INC. | $33.45 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.62 | 2024 | Ocrevus Zunovo |
| Eisai INC. | $21.41 | 2024 | |
| Mallinckrodt Hospital Products INC. | $20.89 | 2021 | |
| Lilly USA, LLC | $14.37 | 2025 | Kisunla |
| Biogen, INC. | $13.97 | 2023 | Vumerity, Tysabri |
| Supernus Pharmaceuticals, INC. | $13.63 | 2022 | |
| Novo Nordisk INC | $12.92 | 2019 | |
| Almatica Pharma LLC | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Reiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.